Menu
Search
|

Menu

Close
X

Atara Biotherapeutics Inc ATRA.OQ (NASDAQ Stock Exchange Global Select Market)

15.24 USD
-- (--)
As of Sep 18
Previous Close 15.24
Open --
Volume --
3m Avg Volume 273,239
Today’s High --
Today’s Low --
52 Week High 43.85
52 Week Low 11.89
Shares Outstanding (mil) 30.56
Market Capitalization (mil) 495.06
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-3.037
FY18
-5.226
FY17
-3.993
FY16
-2.750
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
--
7.91
Price to Book (MRQ)
vs sector
2.19
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
0.00
14.55
LT Debt to Equity (MRQ)
vs sector
0.00
10.20
Return on Investment (TTM)
vs sector
-36.94
14.48
Return on Equity (TTM)
vs sector
-37.81
15.78

EXECUTIVE LEADERSHIP

Pascal Touchon
President, Chief Executive Officer, Director, Since 2019
Salary: --
Bonus: --
Utpal Koppikar
Chief Financial Officer, Since 2018
Salary: $240,289.00
Bonus: $189,771.00
Joseph Newell
Executive Vice President, Chief Technical Operations Officer, Since 2017
Salary: $365,000.00
Bonus: $155,490.00
Mina Kim
Senior Vice President, General Counsel, Secretary, Since 2019
Salary: $266,827.00
Bonus: $101,730.00
Derrell Porter
Senior Vice President,Head of Commercial, Since 2017
Salary: $235,846.00
Bonus: $221,611.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

611 Gateway Blvd Ste 900
SOUTH SAN FRANCISCO   CA   94080-7015

Phone: +1650.2788930

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

SPONSORED STORIES